Adare Pharma Solutions (CDMO) – Woodbury, MN
Legal trust name NexPoint Life Sciences II DST
Talk to a 1031 specialistData updated Nov 20, 2025
Offering size$40.5M
Asset typeOffice
LocationMulti-state
FinancingNot disclosed
Regulation D exemptionRule 506(c)
Sponsor-reported potential 721/UPREIT exitNo
First filedJun 22, 2023
Last filedNov 20, 2025
Minimum$100k
DST interests are illiquid private securities. You may lose some or all of your investment. Distributions, tax treatment, and exit timing are not guaranteed. Review the current Private Placement Memorandum before investing.
Still operating, no exit yet
NexPoint announced on Dec 18, 2025 that the $42 million NexPoint Life Sciences II DST was 'fully subscribed' (equity raise completed), not that it went full cycle; no property disposition, sale, or 721-UPREIT exchange has been announced, per NexPoint's own press release and offerings page [1][2].
Supporting evidence
First filedJun 22, 2023
Latest filingNov 20, 2025
Filings tracked19
View filing on SEC EDGARForm D is an issuer notice filing. A filing does not mean the SEC approved, endorsed, or verified the offering.
In the news
Frequently asked questions
Is Adare Pharma Solutions (CDMO) – Woodbury, MN currently active?
Adare Pharma Solutions (CDMO) – Woodbury, MN is part of the researched historical archive. “Active” reflects the latest public record and does not confirm that interests remain available.
Where does Top1031 get the data for Adare Pharma Solutions (CDMO) – Woodbury, MN?
Top1031 tracks this offering from SEC Form D filings and cited sponsor disclosures. Filing data may lag current subscriptions and does not mean the SEC approved or verified the offering.